Rani Therapeutics

Develops oral delivery for biologic drugs

San Jose, California, United States

About Rani Therapeutics

Rani Therapeutics focuses on delivering biologic drugs in a more patient-friendly way. Biologics are complex medications used to treat chronic diseases, and they are usually given through painful injections. Rani Therapeutics has created a technology that allows these injectable drugs to be taken as oral capsules, making it easier for patients to manage their treatment. The company targets various chronic conditions, including diabetes and rheumatoid arthritis, and works with healthcare providers and pharmaceutical companies. Unlike traditional methods, their oral delivery system aims to enhance patient compliance and improve quality of life. Rani Therapeutics generates revenue through partnerships and licensing their technology, and their preclinical studies show that their capsules are as effective as injections. The goal is to make biologic treatments more accessible and less invasive for patients.

San Jose, CaliforniaHeadquarters
2012Year Founded
$175.6MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Risks

Increased competition from companies like Celltrion threatens Rani's market share.
Reliance on partnerships may pose risks if collaborations do not succeed.
Recent financial moves suggest potential strain on Rani's R&D investment capacity.

Differentiation

RaniPill capsule offers a unique oral alternative to injectable biologics.
Extensive intellectual property portfolio strengthens Rani's competitive position in the market.
Focus on chronic diseases like diabetes and rheumatoid arthritis enhances market relevance.

Upsides

Partnerships with Celltrion and ProGen expand Rani's product development capabilities.
Growing biologics market increases demand for innovative delivery methods like RaniPill.
FDA's favorable stance on biosimilars supports Rani's oral biosimilar product introductions.

Funding

Total raised$175.57 M
Latest valuation$345.00 M
StageIPO
POST IPO EQUITY
6/30/2024
$10
POST IPO DEBT
7/31/2022
$45
IPO
6/30/2021
$73
SERIES E
11/30/2020
$69
$345.00 M
SERIES A
5/31/2012
$4
$20.00 M